Advanced

Plasma β-amyloid in Alzheimer's disease and vascular disease

Janelidze, Shorena LU ; Stomrud, Erik LU ; Palmqvist, Sebastian LU ; Zetterberg, Henrik LU ; Van Westen, Danielle LU ; Jeromin, Andreas; Song, Linan; Hanlon, David; Tan Hehir, Cristina A. and Baker, David, et al. (2016) In Scientific Reports 6.
Abstract

Implementation of amyloid biomarkers in clinical practice would be accelerated if such biomarkers could be measured in blood. We analyzed plasma levels of Aβ42 and Aβ40 in a cohort of 719 individuals (the Swedish BioFINDER study), including patients with subjective cognitive decline (SCD), mild cognitive impairment (MCI), Alzheimer's disease (AD) dementia and cognitively healthy elderly, using a ultrasensitive immunoassay (Simoa platform). There were weak positive correlations between plasma and cerebrospinal fluid (CSF) levels for both Aβ42 and Aβ40, and negative correlations between plasma Aβ42 and neocortical amyloid deposition (measured with PET). Plasma levels of Aβ42 and Aβ40 were reduced in AD dementia compared with all other... (More)

Implementation of amyloid biomarkers in clinical practice would be accelerated if such biomarkers could be measured in blood. We analyzed plasma levels of Aβ42 and Aβ40 in a cohort of 719 individuals (the Swedish BioFINDER study), including patients with subjective cognitive decline (SCD), mild cognitive impairment (MCI), Alzheimer's disease (AD) dementia and cognitively healthy elderly, using a ultrasensitive immunoassay (Simoa platform). There were weak positive correlations between plasma and cerebrospinal fluid (CSF) levels for both Aβ42 and Aβ40, and negative correlations between plasma Aβ42 and neocortical amyloid deposition (measured with PET). Plasma levels of Aβ42 and Aβ40 were reduced in AD dementia compared with all other diagnostic groups. However, during the preclinical or prodromal AD stages (i.e. in amyloid positive controls, SCD and MCI) plasma concentration of Aβ42 was just moderately decreased whereas Aβ40 levels were unchanged. Higher plasma (but not CSF) levels of Aβ were associated with white matter lesions, cerebral microbleeds, hypertension, diabetes and ischemic heart disease. In summary, plasma Aβ is overtly decreased during the dementia stage of AD indicating that prominent changes in Aβ metabolism occur later in the periphery compared to the brain. Further, increased levels of Aβ in plasma are associated with vascular disease.

(Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Scientific Reports
volume
6
publisher
Nature Publishing Group
external identifiers
  • scopus:84973333119
  • wos:000376876900001
ISSN
2045-2322
DOI
10.1038/srep26801
language
English
LU publication?
yes
id
5d9dca97-1419-4dcc-99ab-c8c30910c8c4
date added to LUP
2016-07-18 13:13:52
date last changed
2017-05-29 13:12:02
@article{5d9dca97-1419-4dcc-99ab-c8c30910c8c4,
  abstract     = {<p>Implementation of amyloid biomarkers in clinical practice would be accelerated if such biomarkers could be measured in blood. We analyzed plasma levels of Aβ42 and Aβ40 in a cohort of 719 individuals (the Swedish BioFINDER study), including patients with subjective cognitive decline (SCD), mild cognitive impairment (MCI), Alzheimer's disease (AD) dementia and cognitively healthy elderly, using a ultrasensitive immunoassay (Simoa platform). There were weak positive correlations between plasma and cerebrospinal fluid (CSF) levels for both Aβ42 and Aβ40, and negative correlations between plasma Aβ42 and neocortical amyloid deposition (measured with PET). Plasma levels of Aβ42 and Aβ40 were reduced in AD dementia compared with all other diagnostic groups. However, during the preclinical or prodromal AD stages (i.e. in amyloid positive controls, SCD and MCI) plasma concentration of Aβ42 was just moderately decreased whereas Aβ40 levels were unchanged. Higher plasma (but not CSF) levels of Aβ were associated with white matter lesions, cerebral microbleeds, hypertension, diabetes and ischemic heart disease. In summary, plasma Aβ is overtly decreased during the dementia stage of AD indicating that prominent changes in Aβ metabolism occur later in the periphery compared to the brain. Further, increased levels of Aβ in plasma are associated with vascular disease.</p>},
  articleno    = {26801},
  author       = {Janelidze, Shorena and Stomrud, Erik and Palmqvist, Sebastian and Zetterberg, Henrik and Van Westen, Danielle and Jeromin, Andreas and Song, Linan and Hanlon, David and Tan Hehir, Cristina A. and Baker, David and Blennow, Kaj and Hansson, Oskar},
  issn         = {2045-2322},
  language     = {eng},
  month        = {05},
  publisher    = {Nature Publishing Group},
  series       = {Scientific Reports},
  title        = {Plasma β-amyloid in Alzheimer's disease and vascular disease},
  url          = {http://dx.doi.org/10.1038/srep26801},
  volume       = {6},
  year         = {2016},
}